IP Library › Granted Patent US 10,301,608
Granted Patent B2
US 10,301,608 · App. 15/320,490 · Granted May 28, 2019

Variants of phosphotriesterase for the hydrolysis and detoxification of nerve agents

Inventors: Frank M. Raushel (College Station, TX); Andrew N. Bigley (North Zulch, TX)
Assignee: The Texas A&M University System
C12N9/16A62D3/02C12Y301/03008C12Y301/08001A62D2101/02A62D2101/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,301,608
App. No.
15/320,490
Granted
May 28, 2019
Kind
B2
Abstract

Variants of phosphotriesterase have been created that exhibit enhanced hydrolysis of V-type and G-type nerve agents over wild-type phosphotriesterase. V- and G-type nerve agents have an S P and R P enantiomer. The S P enantiomers are more toxic. V-type nerve agents are among the most toxic substances known. Variants of phosphotriesterase can prefer to hydrolyze one enantiomer of VX over the other enantiomer.

Claims (1)

1. A synthetic amino acid sequence comprising the amino acid sequence of L7ep-3a (SEQ ID NO: 5) and functioning by hydrolyzing an organophosphate nerve agent.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jan 17, 2024
From: TEXAS A&M UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066340/0441 →
Continuity (2)
Provisional Application 62015156 · Jun 20, 2014
Related Publication 20170218348A1 · Aug 3, 2017
Cited By (1)
US 12,680,090